Professor Chun-Ying Wu


Office:守仁樓三樓 R327-1 室

Contact number:(02) 2826-7155


○ 臺大 醫學博士

○ 哈佛大學 法學碩士暨公共衛生碩士

● Current position

○ 國立陽明交通大學生物醫學資訊研究所教授兼所長

○ 國立陽明交通大學醫學院執行副院長

○ 臺北榮民總醫院轉譯研究科主任


○ 國立陽明交通大學醫學院副院長

○ 科技部公共衛生與社會醫學部召集人

○ 國立陽明交通大學生物醫學資訊研究所所長


○ 2018年 醫療典範獎 (Medical Model Award, 2018)

○ 2016年 國家新創獎 (National Innovation Award, 2016)

○ 2015年 傑出研究獎 (Outstanding Research Award, 2015)

○ 2015年 亞太新興領袖獎 (Asia Pacific Emerging Leadership Lecturer, 2015)

○ 2013年 國立陽明大學 教學績優琉璃獎座 (Best Teaching Lectureship Glass Award, NYMU, 2013)

○ Advances in Digestive Medicine主編 (Editor-in-Chief)

○ Journal of Gastroenterology & Hepatology副主編 (Associate Editor)

○ Gut編輯委員 (Editor)

Research interest


Books (or research publications)

○ 代表著作

  1. Wu CY*, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma following liver resection. JAMA 2012 Nov 12, 308(18): 1906-13 (SCI, IF 47.661, 3/154)
  2. Wu CY*, Wu MS, Kuo KN, Chen YJ, Wang CB, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010 Jun; 28(18): 2952-7. (SCI, IF 26.303, 4/222)
  3. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY*. Association of daily aspirin therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019 Mar 18, Epub ahead of print.
  4. Yeo YH, Ho HJ, Yang HI…, Wu CY*, Nguyen MH. The HBsAg seroclearance rate and predictors in adults with chronic hepatitis B: a systematic review and meta-analysis. Gastroenterology 2019 Feb; 156(3): 635-46.
  5. Wu CY*, Lin JT , Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogues therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014 Jul; 147(1): 143-51.e5 (SCI, IF 20.773, 1/80)
  6. Wu CY*, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, Lin JT. Histamine-2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010 Oct; 139(4): 1165-71 (SCI, IF 20.773, 1/80)
  7. Wu CY*, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009 Nov; 137(5):1641-8 (SCI, IF 20.773, 1/80)
  8. Hsu YC, Yip TCF, Ho HJ, Wong VWS, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GLH, Wu CY*. Predicting hepatocellular carcinoma with population-wide data in previously untreated Asians on antivirals for chronic hepatitis B. J Hepatol 2018 Aug; 69(2): 278-85 (SCI, IF 14.911, 4/80).
  9. Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY*. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut 2018 Jan; 67(1): 20-7 (SCI, IF 17.016, 2/80)
  10. Wu CY*, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut 2016 Apr; 65(4): 693-701 (SCI, IF 17.016, 2/80)
  11. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY*. Association between antiviral therapy and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015 Mar; 64(3): 495-503 (SCI, IF 17.016, 2/80)
  12. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY*. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013 Apr; 62(4): 606-15 (SCI, IF 17.016, 2/80)
  13. Wu CY*, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Long term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut 2011 Aug; 60(8): 1038-42 (SCI, IF 17.016, 2/80)
  14. Wu CY*, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007 Jun;56(6):782-9 (SCI, IF 17.016, 2/80)
  15. Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY*. Association between nucleos(t)ide analogues and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma following radiofrequency ablation. Hepatology 2016 May; 63(5): 1517-27 (SCI, IF 14.079, 5/80)
  16. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY*. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014 Apr; 59(4):1293-302 (SCI, IF 14.079, 5/80)
  17. Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY*. Postoperative peg-interferon plus ribavirin associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 2013 Jul; 58(1): 150-7 (SCI, IF 14.079, 5/80)
  18. Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY*. Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. Hepatology 2012 Aug 56(2): 698-705 (SCI, IF 14.079, 5/80)